← Back to all trials
Recruiting
NCT06816459
Sensory Tests of Cigarettes for Identification of Flavors in Current Daily Smoking Adults
Conditions: Cigarette Smoking-Related Carcinoma
Sex: All
Ages: 21 Years – N/A
Healthy volunteers: Yes
Phase: EARLY_PHASE1
Enrollment: 30
Sponsor: Roswell Park Cancer Institute
Location: Roswell Park Cancer Institute Buffalo New York
Summary
This clinical trial tests how well current daily smoking adults can identify flavors of cigarettes. Menthol cigarettes account for 31 percent of cigarettes sold in the United States. Flavors such as menthol play an important role in the start and continued use of tobacco products. Two ways users experience flavor is through smell and taste. Menthol has cooling and numbing properties that can increase perceptions of smoothness and reduce the perceived harshness of smoke. Menthol adds a taste and aroma commonly described as "minty". The effect of menthol flavoring on smoking behavior has been studied. Use of menthol cigarettes has been associated with greater nicotine dependence and is associated with both fewer quit attempts and lower odds of quit success. In 2022, the Food and Drug Administration proposed to restrict the use of menthol as a flavor in cigarettes. Menthol has already been banned in Canada, the United Kingdom and the European Union. In late 2022, a restriction on all flavored tobacco products went into effect in California (CA), prompting the tobacco industry to introduce substitute products that did not contain menthol. It is important to find out whether New York (NY) adult smokers who smoke menthol cigarettes can identify and characterize flavors in the same cigarette brand as sold in NY versus CA following the ban of menthol cigarettes in 2022.
Eligibility Criteria
Inclusion Criteria:
* Aged 21 years or older
* Current daily smoker of factory-made menthol cigarettes
* General good health (assessed by self-rated health item)
* Completion of Brief Smell Identification Test (B-SIT) with no identification of deficits
Exclusion Criteria:
* Daily concurrent use of other tobacco products (e.g., e-cigarettes, cigars, smokeless tobacco)
* Known allergies to mint (peppermint, spearmint), menthol
* Self-reported olfactory or taste deficits
* Pregnant or nursing participants, as indicated by self-report
* History of medications known to interfere with sense of smell
* Positive diagnosis of coronavirus 2019 (COVID-19) within 10 days of enrollment
* Current upper respiratory infection or sinus congestion (e.g., cold, flu, seasonal allergies) (by self report)
Source: ClinicalTrials.gov (NCT06816459). StuddyBuddy aggregates publicly available trial information.